- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Norland’s Paris scanner hits market
Bone densitometry firm Norland Medical Systems continues to make progress in rolling out its Paris ultrasound bone measurement system. The company has begun delivery of Paris systems to European and Pacific Rim customers, and is shipping Paris to
Bone densitometry firm Norland Medical Systems continues to make progress in rolling out its Paris ultrasound bone measurement system. The company has begun delivery of Paris systems to European and Pacific Rim customers, and is shipping Paris to physician investigators for testing as part of the Food and Drug Administration's premarket approval process. Norland expects to file its PMA this quarter.
In other company news, Norland has received FDA 510(k) clearance to market a fracture risk assessment feature for its pDEXA x-ray peripheral bone densitometer. Physicians can use the feature to select patients who might benefit from preventive treatment to avoid fractures, as well as to make clinical decisions regarding therapeutic intervention, according to White Plains, NY-based Norland.
Can Portable Dual-Energy X-Ray be a Viable Alternative to CT in the ICU?
September 13th 2024The use of a portable dual-energy X-ray detector in the ICU at one community hospital reportedly facilitated a 37.5 percent decrease in chest CT exams in comparison to the previous three months, according to research presented at the American Society of Emergency Radiology (ASER) meeting in Washington, D.C.
New Meta-Analysis Examines MRI Assessment for Treatment of Esophageal Cancer
September 12th 2024Diffusion-weighted MRI provided pooled sensitivity and specificity rates of 82 percent and 81 percent respectively for gauging patient response to concurrent chemoradiotherapy for esophageal cancer, according to new meta-analysis.
Study for Emerging PET/CT Agent Reveals ‘New Standard’ for Detecting Clear Cell Renal Cell Carcinoma
September 11th 2024Results from a multicenter phase 3 trial showed that the PET/CT imaging agent (89Zr)Zr-girentuximab had an 85.5 percent mean sensitivity rate for the diagnosis of clear cell renal cell carcinoma.
Can Radiomics and Autoencoders Enhance Real-Time Ultrasound Detection of Breast Cancer?
September 10th 2024Developed with breast ultrasound data from nearly 1,200 women, a model with mixed radiomic and autoencoder features had a 90 percent AUC for diagnosing breast cancer, according to new research.
